Dyadic International (DYAI) Cash & Current Investments (2017 - 2026)
Dyadic International's (DYAI) quarterly Cash & Current Investments came in at $8.0 million in Q1 2026, up 8.32% year-over-year from $7.3 million in Q1 2025, and down 29.54% quarter-over-quarter from $11.3 million in Q4 2025.
Analysis
Dyadic International (DYAI) Cash & Current Investments (2017 - 2026) Analysis & Trends
Dyadic International has disclosed Cash & Current Investments across 10 years of filings, most recently posting $8.0 million for Q1 2026.
- In Q1 2026, Cash & Current Investments rose 8.32% year-over-year to $8.0 million; the TTM figure through Mar 2026 stood at $8.0 million (up 8.32% YoY), while the FY2025 annual figure was $11.3 million, up 21.97% from the prior year.
- Cash & Current Investments came in at $8.0 million for Q1 2026 at Dyadic International, down from $11.3 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $15.4 billion in Q1 2022 to a low of $7.3 million in Q4 2023.
- Average Cash & Current Investments over 5 years is $918.6 million, with a median of $11.3 million recorded in 2025.
- Year-over-year, Cash & Current Investments surged 56596.26% in 2022 and tumbled 99.92% in 2023.
- Over 5 years, Cash & Current Investments stood at $12.6 million in 2022, then plunged by 42.54% to $7.3 million in 2023, then grew by 27.54% to $9.3 million in 2024, then gained by 21.97% to $11.3 million in 2025, then declined by 29.54% to $8.0 million in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $8.0 million in Q1 2026, $11.3 million in Q4 2025, and $13.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.69 Bn | 192.70 Bn | 7.24 Bn | 13.99 Bn |
| 2 | Gilead Sciences | 179.87 Bn | 176.70 Bn | 6.22 Bn | 3.18 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 7.85 Bn |
| 4 | Regeneron Pharmaceuticals | 81.70 Bn | 73.71 Bn | 3.93 Bn | 7.99 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 5.18 Bn |
| 6 | Moderna | 54.28 Bn | 49.14 Bn | 52.00 Mn | 5.14 Bn |
| 7 | Alnylam Pharmaceuticals | 33.02 Bn | 29.71 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | 1.29 Bn |
| 9 | Roivant Sciences | 29.27 Bn | 29.27 Bn | 1.16 Mn | - |
| 10 | Dyadic International | 17.59 Mn | 9.63 Mn | - | 7.96 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 7.96 Mn |
| Dec 31, 2025 | 11.30 Mn |
| Sep 30, 2025 | 13.50 Mn |
| Jun 30, 2025 | 14.20 Mn |
| Mar 31, 2025 | 7.35 Mn |
| Dec 31, 2024 | 9.26 Mn |
| Sep 30, 2024 | 9.92 Mn |
| Jun 30, 2024 | 10.10 Mn |
| Mar 31, 2024 | 12.04 Mn |
| Dec 31, 2023 | 7.26 Mn |
| Sep 30, 2023 | 8.18 Mn |
| Jun 30, 2023 | 10.13 Mn |
| Mar 31, 2023 | 11.74 Mn |
| Dec 31, 2022 | 12.64 Mn |
| Sep 30, 2022 | 14.20 Mn |
| Jun 30, 2022 | 15.64 Mn |
| Mar 31, 2022 | 15.44 Bn |
| Dec 31, 2021 | 20.26 Mn |
| Sep 30, 2021 | 22.75 Mn |
| Jun 30, 2021 | 25.60 Mn |